

# **Whole genome amplification from single cell and its optimization for better genomic coverage**

Serdar Coskun, Wafa Qubbaj and Osama  
Alsmadi

King Faisal Specialist Hospital and Research  
Center, Riyadh, Saudi Arabia

# **Whole genome amplification (WGA)**

- **WGA is an in vitro method to amplify DNA in a sample to generate amplified DNA for further molecular genetic analysis**
- **WGA is particularly useful for samples with limited DNA content**

- **Preimplantation genetic diagnosis (PGD) relies on the genetic material taken from a single cell**
- **PGD utilizes direct PCR on the lysed single cells**
- **PCR has enough sensitivity for DNA analysis in a single cell**

- **Low quantity DNA in a single cell presents a number of challenges including**
  - **contamination**
  - **amplification failure**
  - **preferential amplification**
  - **allele dropout (ADO)**
- **Single cell can be analyzed only once**
- **Independent confirmation and additional analysis are impossible**
  
- **Will WGA be a solution?**

## **WGA methods used in PGD**

- Primer extension preamplification PCR (PEP-PCR)**
- Degenerate oligonucleotide primed PCR (DOP-PCR)**
- OmniPlex WGA**
- Multiple displacement amplification (MDA)**

# Primer extension preamplification-PCR (PEP-PCR)

- **First introduced in 1992 in the analysis of single sperm typing to study genetic recombination**
- **Total degenerate 15-mer PCR primers (hexamers were not successful)**
- **Generates a smear of DNA fragments that are visible on agarose gel**
- **Coverage at least 78%**

# Protocol

## – **Fifty amplification cycles**

- Denaturation 1-minute at 92°C
- Annealing 2-minute step at 37°C
- Ramping step of 0.1°C/sec to 55°C
- Polymerase extension 4-minute step at 55°C by using Taq polymerase

# Improved PEP (IPEP)

- **IPEP differs from original PEP**
  - cell lysis in Expand Lysis buffer
  - use of a mix of *Taq* polymerase and proofreading *Pwo* polymerase in whole genome amplification
  - an additional cyclical elongation step at 68°C for 30 seconds before the denaturation step at 94°C

- **IPEP-PCR is more effective than the conventional PEP-PCR**
- **IPEP-PCR supports**
  - **microsatellite analysis**
  - **accurate sequencing**
  - **mutation detection methods**

- **PEP in PGD**


- **Aspartylglucomaminuria**
- **Infantile neuronal ceroid lipofuscinosis**
- **Familial amyloidosis of the Finnish type**
- **Beta-thalassemia**
- **Familial adenomatous polyposis coli**
- **Cystic fibrosis**
- **Duchenne muscular dystrophy**

# Degenerate oligonucleotide-primed PCR (DOP-PCR)


- **Partially degenerate sequence oligonucleotides**
  - 5'-CCGACTCGAGNNNNNNATGTGG-3'
  - Primers randomly anneal to the genome
- **Low initial annealing temperature, ensures priming from multiple sites**
- **Annealing temperature is increased to allow more specific priming**
- **Coverage is theoretically genome wide**

5' CCGACTCGAG NNNNNN ATGTGG 3'

1. Low stringency PCR ( $T_a = 30^\circ\text{C}$ ; 5 cycles)  
→ frequent priming at multiple sites



2. Higher stringency PCR ( $T_a = 62^\circ\text{C}$ ; 35 cycles)  
→ specific priming of pre-amplified sequences



- **DOP-PCR allowed first CGH on single cell**
  - **Provided reliable detection of trisomies and sex in a blind study**
- **Hybridization of DOP-PCR products to normal metaphase chromosomes produced**
  - **strong even signals with no obvious sites of amplification deficiency or excess**

## Genomic coverage: proportion of successful amplifications at specific loci after various forms of WGA

Locus	WGA methods					
	PEP	T-PCR	DOP25	DOP50	alu	Total
D21S11	1.00	0.88	0.73	0.80	0.41	0.77
D21S1414	0.90	0.65	0.76	0.85	0.45	0.76
D18S535	0.90	0.69	1.00	0.95	0.80	0.86
CFTR	0.95	0.95	0.74	1.00	0.86	0.92
[beta]-globin	0.90	0.94	0.86	0.91	0.52	0.85
FACC	0.80	0.41	0.81	0.91	0.19	0.64
Amg X	0.91	0.82	0.95	0.80	0.47	0.80
Amg Y	0.90	0.50	0.80	0.80	0.67	0.73
APC	0.95	0.91	0.91	0.95	0.80	0.94
HMSH2	0.90	0.87	0.89	0.91	0.72	0.86
Total	0.91	0.76	0.85	0.89	0.59	0.81

- **CGH with PEP amplified DNA technique failed to give any accurate results due to signal intensity**
- **DOP25 was particularly successful as incorporation of fluorescent nucleotides during the second amplification reaction**

# OmniPlex




- **OmniPlex is a whole genome amplification method allows generating a representative amplification of genomic DNA**
- **Utilizes amplification technology based upon**
  - **random fragmentation of genomic DNA**
  - **conversion of the resulting fragments to PCR amplifiable OmniPlex Library molecules flanked by universal priming sites**
  - **OmniPlex library is then PCR amplified using universal oligonucleotide primers**

# Protocol


- **Proteinase K digestion** 1 hr at 50° C
- **4 min at 99° C for fragmentation**
- **Sample cooled down to 4 °C in a thermocycler**
- **3 µl library mix added to each proteinase K-digested cell**
  - 2 min at 95° C
  - down to 4° C and kept on ice
  - 1 µl of library preparation enzyme
- **Thermo cycling**
  - 20 min at 16° C,
  - 20 min at 24° C,
  - 20 min at 37° C,
  - 5 min at 75° C
  - cool down to 4° C.
- **60 µl amplification mastermix added to the sample**
- **PCR**
  - 3 min at 95° C
  - 25 cycles of 30 s at 94° C
  - 5 min at 65° C
  - cool down to 4° C

- **OmniPlex successfully amplified genomic material from sources**
  - **Saliva**
  - **whole blood**
  - **blood card**
  - **buccal swab**
  - **bacterial artificial chromosome**
  - **formalin-fixed, paraffin-embedded tissues**

- **PGD for  $\beta$ -thalassaemia and HLA typing**
  - **Amplification efficiency**      **88-94%**
  - **ADO**      **6-19%**


**A****B****C**

# OmniPlex in Array



# Multiple displacement amplification (MDA)

- MDA is an isothermal method that utilizes
  - bacteriophage phi29 DNA polymerase
  - random hexamer (NNNNNN) for amplification



- **MDA is capable of generating large fragments (>10 kb in size)**
- **Internal proofreading activity results in much lower misincorporation rates relative to *Taq* DNA polymerase**

# Use in PGD

- **CGH**
- **aCGH**
- **Beta-thalassemia**
- **Morquio disease**
- **X-linked retinoschisis**
- **Duchenne muscular dystrophy**
- **X-linked adrenoleukodystrophy**
- **Non-ketotic hyperglycinaemia**
- **Brachydactyly type B**
- **Diandric complete hydatidiform mole**
- **Marfan syndrome**
- **Fragile X syndrome**
- **Huntington disease**
- **Zellweger syndrome**
- **Cystic Fibrosis**

# Preimplantation Genetic Haplotyping (PGH)



- **127 PGH for 101 couples**
  - Cystic fibrosis (50 cycles, 37 couples)
  - Huntington disease (29, 24)
  - Duchenne/Becker muscular dystrophy (17, 15)
  - Spinal muscular atrophy (SMA) (8, 6)
  - Epidermolysis bullosa (EB) (7, 4)
  - Sickle cell disease (SCD) (6, 6)
  - Alport syndrome (3, 2)
  - Fragile X syndrome (3, 3)
  - Prader-Willi syndrome (1, 1)
  - Familial partial lipodystrophy (1, 1)
  - Haemophilia A (1,1)
  - CF + Haemophilia A (1, 1)
- **26 babies born, 13 ongoing pregnancies**
- **MDA coupled with PGH provides a robust, efficient and successful alternative to single cell PCR for monogenic diseases**

<b>Achondroplasia</b>	<b>Maple syrup urine disease</b>
<b>Adreno Leukodystrophy (ADL)</b>	<b>Metachromatic Leukodystrophy</b>
<b>Albinism, oculocutaneous type IA</b>	<b>Microphthalmia/ anophthalmia</b>
<b>Alpha thalassemia/mental retardation syndrome</b>	<b>Mucopolysaccharidosis, type I (Hurler Syndrome)</b>
<b>Arginino Succinic Acidemia</b>	<b>mucopolysaccharidosis, type II (Hunter syndrome)</b>
<b>Ataxia Telangiectasia Mutated</b>	<b>Mucopolysaccharidosis, type IVA, Morquio syndrome A</b>
<b>Biotinidase deficiency</b>	<b>mucopolysaccharidosis, type VI (Maroteaux-Lamy syndrome)</b>
<b>Bosley-Salih-Alorainy syndrome</b>	<b>Niemann Pick disease (NPD)</b>
<b>B-Thalassemia</b>	<b>Non-ketotic hyperglycemia</b>
<b>Canavan Disease</b>	<b>Osteogenesis Imperfecta Type IV</b>
<b>Carnitine Acylcarnitine translocase deficiency</b>	<b>Phenol Ketonuria (PKU)</b>
<b>Chronic Granulomatous disease (CGD)</b>	<b>Progressive Familial Intrahepatic Cholestasis 1</b>
<b>Citrullinemia</b>	<b>Propionic Acidaemia</b>
<b>Congenital Adrenal Hyperplasia (CAH)</b>	<b>Sanfilippo type B (MPS-IIIB)</b>
<b>Cystic Fibrosis</b>	<b>Sanjad Sakati Syndrome</b>
<b>Duchenne muscular dystrophy (DMD)</b>	<b>Severe combined immunodeficiency disease</b>
<b>Ehlers-Danlos Syndrome</b>	<b>Sickle cell</b>
<b>Fragile X</b>	<b>Smith Lemli Opitz Syndrome; SLOS</b>
<b>Galactosomia</b>	<b>Spinal muscular atrophy / Werdnig Hoffmann</b>
<b>Glucose-6-phosphate dehydrogenase deficiency</b>	<b>Sulfite Oxidase deficiency</b>
<b>Glutaric Acidemia type 1</b>	<b>Tyrosinemia type I</b>
<b>Glycogen storage disease type II, Pompe disease</b>	<b>Very long-chain acyl-CoA dehydrogenase deficiency</b>
<b>GM1-Gangliosidosis</b>	<b>Wiskott-Aldrich Syndrome</b>
<b>Hereditary non-syndromic sensorineural deafness</b>	<b>X-linked Hydrocephalus</b>
<b>Hyperinsulinemia</b>	<b>Zellweger Syndrome</b>

# DOP vs MDA in CGH

- **189 oocyte or PB using one of two WGA methods**
  - **DOP-PCR 159/183 (86.6%)**
    - yielding 200–4,000 bp smear
  - **MDA 5/6 (83.3%)**
    - average fragment sizes of 10 000 bp
- **No difference in fluorescence intensities between samples amplified by the DOP-PCR and with the MDA in CGH**

# DOP - MDA - OmniPlex



Uda et al., 2007, Jpn J Infect Dis


- **DOP-PCR, OmniPlex and MDA have been successfully applied in PGD and arrays**
- **Among these WGA technologies**
- **MDA is more widely applied into PGD clinical application than other PCR-based WGA methods**
  - **Very simple to perform**
  - **Requiring only the addition of reagents (primers, polymerase, and nucleotides) in a single, isothermal step**

- **MDA is still facing some challenges such as**
  - **Template independent DNA synthesis (TIDA)**
  - **Allele drop out (ADO)**
- **TIDA has been addressed by technical modifications on the MDA protocol**
  - **reducing the reaction volume resulted in suppression of TIDA (Kumar et al., 2008)**

# MDA Modifications

- A random hexamer (NNNNNN) in kit constituted of a pool of 4096 ( $4^6$ ) primers
- Four primers either non degenerate or partially to complete degenerate with their length ranging from 6 to 10 base pairs were used
  - NNNNNNN
  - GGNNNN
  - AGGGAG
  - GGGCAGGANG
- Primers were NNNNNN random hexamer primer utilized by the Repli-g kit was used as reference
- Temperature
  - 30°C
  - 40°C

# MDA reactions in presence and absence of DNA template



# Affymetrix SNP call analysis

<b>Sample</b>	<b>% SNP Call</b>
<b>Genomic DNA</b>	<b>95.1</b>
<b>Kit 30</b>	<b>96.5</b>
<b>Kit 40</b>	<b>96.3</b>
<b>W30</b>	<b>96.9</b>
<b>W40</b>	<b>95.0</b>

W30 and W40 -- MDA reactions using GGGCAGGANG primer at 30°C and 40°C

# Single cell amplification efficiency

- **NNNNNN** 88%
- **GGNNNN** 72%
- **AGGGAG** <10%
- **GGGCAGGANG** <10%

**MDA of single cell at 40°C had a very low amplification yield compared to 30°C**

# Conclusions

- **Primer and temperature modifications resulted in increasing specific DNA yield and eliminating TIDA in gDNA**
- **They did not help to improve single cell MDA**
- **ADO still presents a challenge to PGD**

# Increasing number of cells

	<b>1 blastomere removed</b>	<b>2 blastomeres removed</b>	<b>P value</b>
<b># of embryos</b>	<b>229</b>	<b>399</b>	
<b># of STRs</b>	<b>740</b>	<b>1334</b>	
<b>MDA failure</b>	<b>34 (15)</b>	<b>20 (5)</b>	<b>0.000</b>
<b>Allele dropout</b>	<b>91 (12.3)</b>	<b>101 (7.6)</b>	<b>0.000</b>

# Effects on Pregnancy and Implantation

	Transferred embryos generated from			Overall
	1 blastomere removed	2 blastomeres removed	Mixture of 1 and 2	
<b>Cycles with embryo transfers</b>	<b>55</b>	<b>58</b>	<b>25</b>	<b>138</b>
<b>Implanted/transferred (%)</b>	<b>28/99 (28)</b>	<b>37/109 (34)</b>	<b>14/51 (31)</b>	<b>79/259</b>
<b>Total pregnant (%)</b>	<b>27 (50)</b>	<b>32 (55)</b>	<b>13 (52)</b>	<b>72</b>


- **Removing two cells improves the efficiency of MDA**
- **ADO is still present**
- **ADO might be an inherent problem with single cell amplifications**

		ADO (a)		
		0.12	0.28	0.35
No. markers (N)	2	0.899	0.607	0.474
	3	0.968	0.754	0.618
	4	0.990	0.846	0.723
	5	0.997	0.903	0.799
	6	0.999	0.939	0.854
	7	1.000	0.962	0.894
	8	1.000	0.976	0.923
	9	1.000	0.985	0.944
	10	1.000	0.991	0.960


( $N = 10$ ,  $a = 0.35$ ) for the detection of trisomy with 95% confidence.

- **With the introduction of**
  - **Karyomapping**
  - **Parental support technology**
  - **DNA fingerprinting**
- **ADO could be overcome during the analysis**


A




B




C




D



E



F



**Thank you**